Currently we test and support the following browsers:
Solid Tumor : Neuroblastoma
Treatment for children with high-risk neuroblastoma is usually done in three phases:
The main goal of this research study is to find out if adding an investigational monoclonal antibody called hu14.18K322A to the first two cycles of induction chemotherapy will result in better tumor responses, compared to treatment given to children in past studies that did not include the antibody.
In addition, we also want to find out if giving this antibody with further cycles of induction, consolidation and MRD therapy will be beneficial. Finally, we want to find out if giving a type of white blood cell from a parent donor, called Natural Killer (NK) cells, starting two days after stem cell infusion, during consolidation therapy, will benefit children with high risk neuroblastoma.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Wayne Furman, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: firstname.lastname@example.org
For all other inquiries about St. Jude Children's Research Hospital studies: email@example.com
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.